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~bstraet Vascular smooth muscle cells (SMC) transform to 
loam cells in the process of atherosclerosis. We have reported 
that SMC derived from the intima of athernsclerotic lesions 
express c-fins, macrophage colony-stimulating factor receptor 
gene, which is not normally expressed in medial SMC. In the 
present study, we demonstrated that transforming rowth factor- 
1~ (TGF-IS) synergistically induced expression of c-f ms in the 
presence of platelet-derived growth factor-BB in human medial 
SMC, a level comparable to that observed in the intima. The 
induction of c-fins was not inhibited by protein kinase C (PKC) 
inhibitor, suggesting that TGF-I~ induces c-fins via a PKC- 
independent pathway. These results suggest hat TGF-I] plays an 
important role in the phenotypic hange of smooth muscle cells to 
macrophage-like cells in the process of atherosclerosis. 
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I. Introduction 
Foam cell formation is the most characteristic event during 
he  process of early atherosclerosis. Foam cells are derived 
"rom both monocyte-derived macrophages and smooth muscle 
.:ells (SMC). Peripheral monocytes enter the subendothelial 
~pace and differentiate to tissue macrophages that actively 
L:ake up lipoprotein cholesterol through receptor-mediated n- 
:locytosis. SMC migrate from the media to the intima of the 
~rterial wall where they proliferate and transform to foam 
:ells [1,2]. We and others have demonstrated that two char- 
~cteristic genes of macrophages, macrophage colony-stimulat- 
:ng factor (M-CSF) receptor gene, encoded by proto-onco- 
gene c-fms, and scavenger eceptor gene, are induced on 
SMC derived from the intima of atherosclerotic lesions [3,4]. 
We speculate that the factors involved in the atherosclerotic 
process cause changes in the regulation of c-fins gene expres- 
sion in normal vascular SMC by inducing a phenotypic 
:hange to macrophage-like cells. Recently, we reported that 
platelet-derived growth factor (PDGF)-BB transiently induces 
gene expression of c-fms in normal vascular SMC through a 
protein kinase C (PKC)-independent pathway [5]; with the 
addition of epidermal or fibroblase growth factor (EGF or 
FGF), the gene expression is similar to that in intimal SMC 
involving PKC activation [6]. In the present study, we found 
that the combination of PDGF-BB and transforming rowth 
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factor-13 (TGF-[3) induces the stable expression of  c-fms in 
normal vascular SMC, to the same extent as in intimal SMC. 
2. Materials and methods 
2.1. Cells 
Human aortic SMC were explanted by the method of Fischer-Dzo- 
ga et al. [7]. Cells were passaged three times by exposure to trypsin 
and seeded in 10 ml of Dulbecco's modified Eagle's medium (DMEM; 
Gibco, Gaithersburg, MD) containing 10% fetal bovine serum in 100- 
mm dishes, and used for experiments at the 4th to 6th passage. Sub- 
confluent cells were cultured in serum-free medium for 24 h before 
experiments and then medial SMC were cultured with DMEM con- 
taining 1% fetal calf serum (FCS) in the presence of both TGF-13 and 
PDGF-BB at 37°C. Protein concentration was determined by the 
BCA assay (Pierce, Rockford, IL). 
2.2. Quantitative analysis of M-CSF receptor mRNA 
Human SMC were treated with a combination of TGF-I~ (1 ng/ml) 
and PDGF-BB (10 ng/ml) for various times (1~,8 h) or with various 
concentrations (0.5-3 ng/ml) of TGF-13 for 8 h in DMEM containing 
1% FCS after incubation in serum-free medium for 24 h. After incu- 
bation with TGF-I~ , total RNA was isolated by the acid-guanidine 
phenol chloroform method [8]. A competitive polymerase chain reac- 
tion method was used to measure M-CSF receptor (c-fins) mRNA 
levels as previously described [3]. 
2.3. RNase protection assay 
A 1.2-kb PstI fragment (2048 3194) of the human c-fms cDNA was 
subcloned into pBluescript II SK(-) (Stratagene, La Jolla, CA), and 
this plasmid was digested with Bglll. A probe specific to human c-fms 
was labeled with [ot-32p]UTP (specific activity 800 Ci/mmol; Amer- 
sham, Arlington Heights, IL) by the method escribed in the instruc- 
tion of the Riboprobe Gemini System (Prornega, Madison, WI). 354- 
bp antisense transcripts were used for the ribonuclease protection 
assay. 
The ribonuclease protection assay was performed by the method 
described in the instructions for the Ribonuclease protection assay kit 
(Ambion Inc., Austin, TX). 25 ~tg of total RNA was hybridized with 
approximately 20 000 cpm of probe overnight at 42°C, and then was 
digested with a mixture of RNase A and RNase TI. Protected frag- 
ments were separated on 5% acrylamide/8 M urea gels. 
3. Results 
mRNA of c-fins was not detected and was not induced by 
10 ng/ml PDGF-BB in human aortic medial SMC using the 
RNase protection assay with a riboprobe of c-fms, whereas 
mRNA of c-fms was detected in human monocyte-derived 
macrophages. In the presence of both 10 ng/ml PDGF-BB 
and 1 ng/ml TGF-[~, mRNA of c-fms was obviously induced 
in human SMC (Fig. 1A). 
To estimate the mRNA level of c-fins, we used a sensitive 
competitive polymerase chain reaction method. In assays of 
All rights reserved. 
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Fig. 1. Ribonuclease protection assay (A) and quantitative analysis (B) of M-CSF receptor mRNAs isolated from vascular SMC. A: Subconflu- 
ent SMC were cultured with 1 ng/ml human TGF-I3 or 10 ng/ml human PDGF-BB. Human monocyte-derived macrophages (HMM) were cul- 
tured as described [3]. 25 lag of total RNA was applied to the ribonuclease protection assay. B: 1 Bg of total RNAs isolated from the cells 
were reverse-transcribed with random hexamer primers. Aliquots of the cDNA products were co-amplified with indicated amounts of the con- 
trol genomic DNA. mRNA levels were estimated by titrating an unknown amount of cDNA against a dilution series containing known 
amounts of the corresponding genomic DNA. 
aortic medial SMC in the presence of both l0 ng/ml PDGF- 
BB and 1 ng/ml TGF-13, the mRNA level was estimated at 
4.0X 10 -2 pg/B1 genomic DNA, whereas they were 0.8 × 10 -2 
pg/gl genomic DNA in the presence of PDGF-BB alone and 
0.002×10 -2 pg/~tl genomic DNA at non-stimulated condi- 
tions (the absence of growth factors). These results indicate 
that the transcription of c-fms in human medial SMC was 
increased 2000-fold in response to both PDGF-BB and 
TGF-13 and the addition of TGF-I3 stimulated mRNA expres- 
sion of c-fins 5-fold as compared with PDGF-BB alone (Fig. 
1B, Table 1). We have recently reported that 5 ng/ml heparin 
binding EGF-like growth factor (HB-EGF) induces the 
mRNA of c-fms to the level of 7.0X10 2 pg/~tl genomic 
DNA which is comparable with that of human monocyte- 
derived macrophages [9]. 
We observed that the combination of PDGF-BB and TGF- 
13 induced the expression of c-fms at 8-12 h after addition to 
the culture medium (Fig. 2A), and the gene expression was 
enhanced 2000-fold in response to these growth factors in 
aortic medial SMC. This enhanced expression of c-fms was 
sustained at least 48 h after exposure to the growth factors. 
The effect of this combination on the c-fms expression was 
dependent on the concentration of TGF-13 and the maximal 
effect was obtained by 1 ng/ml of TGF-13 (Fig. 2B). The 
amount of total RNA/cell was not significantly different be- 
tween untreated cells and growth factor-treated cells. Pretreat- 
ment with protein kinase C inhibitors, staurosporine (50 nM) 
and calphostin C (10 nM), had no significant effect on e-fms 
expression i  the presence of these growth factors (Fig. 3). 
4. Discussion 
mRNA of M-CSF receptor encoded by c-ires was not de- 
tected in normal vascular smooth muscle cells by the protec- 
tion assay, and we found that the mRNA expression in the 
sensitive assay using a competitive polymerase chain reaction 
was extremely low in normal vascular smooth muscle cells 
compared to human monocyte-derived macrophages. The 
M-CSF receptor and PDGF-13 receptor are generally ex- 
pressed in a mutually exclusive manner, i.e. the M-CSF re- 
ceptor is expressed primarily on monocyte-macrophages [10] 
and the PDGF receptor gene is expressed on mesenchymal 
cells [11]. We have recently focused on mechanisms involved 
in the phenotypic change of vascular SMC to phagocytic cells 
which is characterized by expression of the M-CSF receptor 
encoded by c-fms. We have demonstrated that multiple 
growth factors and cytokines regulate c-ires expression i  vas- 
cular SMC which do not normally express this gene [3,5,6,9] 
and that transcription factor PU.1 plays an essential role in 
the phenotypic conversion of vascular smooth muscle cells to 
Table 1 
mRNA expression of c-ires in vascular smooth muscle cells 
mRNA level (x 10 2, pg/pl) fold 
Human aortic medial SMC 
Human monocyte-derived macrophage 
Human aortic medial SMC in the presence of
10 ng/ml PDGF-BB 
10 ng/ml PDGF-BB +1 ng/ml TGF-13 
5 ng/ml HB-EGF 
0.002 1.0 
17.5 8.75 X 10 :~ 
0.8 4.0 x 102 
4.0 2.0 x 10 3 
7.0 3.5 )< 10 3 
Subconfluent human aortic medial smooth muscle cells were cultured with the indicated factors in DMEM containing 1% FCS for 8 h after a 24-h 
pre-incubation in serum-free medium. Human monocyte-derived macrophages, human aortic medial SMC were cultured as described [3]. Total 
RNA was isolated from cells and levels of mRNA expression were estimated by a competitive polymerase chain reaction method and expressed as
genomic -fms concentrations (10 -2 pg/~tl). 
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I'ig. 2. Time- and dose-related xpression of c-fins mRNA in response to TGF-~ in human aortic smooth muscle cells. The subconfluent cells 
,,eere cultured with 1 ng/ml human TGF-I3 and 10 ng/ml human PDGF-BB for the indicated times (A) and with the specified amounts of TGF- 
il and 10 ng/ml human PDGF for 8 h (B). Each value was estimated by a competitive polymerase chain reaction method. 
~nacrophage-like cells by mediating the induction of c-fins 
112]. PDGF-BB induces c-fins expression in the absence of 
,,ther growth factors and cytokines. Although this induction 
,,f c-fins is transient and low [5], we have recently reported 
~hat induction of c-fins by HB-EGF alone is stable and as 
idgh as the expression in intimal SMC isolated from athero- 
~clerotic lesions [9]. Neither TGF-I3, EGF nor FGF alone 
nduces t-~ms expression. In the presence of PDGF-BB, 
~C~ , ~'~0 ~'~,,~ 
.x..o" 
q,,o 
~ !!:~!~ ~9: c-fms 
EGF and FGF strongly induce expression of c-fins, to the 
level seen in intimal SMC [6]. The present study further dem- 
onstrates that TGF-[3 induces the stable expression of c-fms in 
the presence of PDGF-BB in medial SMC, a level comparable 
to that seen in intimal SMC. 
We have reported that c-fins expression i duced by PDGF- 
BB is mediated through PKC-independent pathways and then 
augmented by EGF and FGF through pathways including 
protein kinase C activation [5]. PDGF-BB acts initially to 
render cells competent to respond to progression factors [13] 
and then factors such as EGF and FGF stimulate the signal 
induced by the PDGF-BB homodimer. On the other hand, 
HB-EGF induces high and stable c-lins expression by consec- 
utively stimulating the signals of both PKC-dependent and 
-independent pathways [9]. The potency of the combination 
of TGF-13 and PDGF-BB in c-ires expression is approximately 
5 7 times greater than that of PDGF-BB homodimer alone 
and is close to that of HB-EGF alone. Since the action of 
TGF-[3 is not completely inhibited by PKC inhibitors, a major 
pathway for c-fins expression i  response to TGF-I3 may not 
be PKC activation; the action of TGF-[3 is different from 
those of EGF, FGF, and HB-EGF. These results suggest 
that PKC activation is not essential for stable and high c- 
.['ms expression and that growth factors secreted by cells in 
atherosclerotic lesions may induce c-ires expression via differ- 
ent pathways. Other investigators have recently demonstrated 
that TGF-13 synergistically stimulates cavenger receptor ac- 
tivity together with other growth factors such as PDGF-BB in 
SMC [14], suggesting that TGF-I 3 contributes to the phenotyp- 
ic change of SMC to macrophage-like c lls by inducing both 
c~[ins and scavenger receptor genes in atherosclerotic lesions. 
Fig. 3. Ribonuclease protection assay of M-CSF receptor mRNAs 
isolated from vascular SMC. Subconfluent cells were cultured with 
I ng/ml human TGF-[3 in the presence or absence of protein kinase 
C inhibitors (50 nM staurosporine and 10 nM calphostin C) in 
DMEM containing 1% FCS for 8 h after a 24-h pre-incubation i  
serum-free medium. Thereafter, 25 gg of total RNA was applied to 
ribonuclease protection assay with the RNA probe for human c- 
[ms. 
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